Kura Oncology

Unlock to Claim this listing
Add / Modify Company

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.

Click to rate this company
[Total: 0 Average: 0]

3.3

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

Research and Development: Kura Oncology’s focus on developing targeted cancer therapies could potentially lead to more effective treatments with reduced side effects, positively impacting patients’ quality of life. Sustainable Practices: The company may implement environmentally responsible practices in its laboratories and operations, such as energy-efficient equipment and waste reduction measures. Collaboration: Kura Oncology might collaborate with research partners and academic institutions to share knowledge and collectively advance sustainable practices in the biopharmaceutical industry.Patient Outcomes: Kura Oncology’s precision cancer therapies could significantly improve patient outcomes, extending survival rates and enhancing quality of life. Healthcare Access: The company’s therapies could contribute to increased access to innovative cancer treatments, especially for patients with specific genetic mutations. Medical Innovation: Kura Oncology’s research and development efforts might drive innovations in cancer treatment, benefiting patients globally.Leadership Structure: Kura Oncology’s governance structure likely includes a leadership team responsible for strategic decisions and ethical practices. Ethical Research: The company may uphold high ethical standards in its clinical trials and research activities, ensuring patient safety and data integrity. Transparency: Kura Oncology may emphasize transparent communication with stakeholders about its research progress, trial results, and ethical considerations.Value Creation: Kura Oncology’s ESG efforts could contribute to its long-term financial success by enhancing its reputation, attracting responsible investors, and improving operational efficiency. Innovation: The company’s commitment to precision cancer therapies might lead to breakthrough treatments, increasing market value and growth potential. Operational Efficiency: By implementing sustainable practices, Kura Oncology may achieve cost savings through reduced resource consumption and streamlined operations. Investor Confidence: Strong ESG performance can attract investors who prioritize companies with responsible and ethical business practices.atient Safety: Kura Oncology’s commitment to patient safety ensures that clinical trials are conducted with utmost care and adherence to ethical guidelines. Regulatory Compliance: The company’s operations likely adhere to ethical standards and regulatory requirements for drug development and clinical research.

Eligible Awards

Coming Soon

Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$480,100,000.00

Website Traffic

Employee Rating

4.6

Customer Rating

3

Company Size

100-1000

ESG Risk Rating

3

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.